ACTH(4-10) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-17. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
== External links == FDA Alert on Bextra withdrawal Large systematic review of adverse renal and arrhythmia risk of valdcoxib and other COX-2 inhibitors, JAMA 2006 Archived 2020-11-05 at the Wayback Machine
=== Articles === Ben-Amos, I.K. (1997). "Human Bonding: Parents and Their Offspring in Early Modern England." Discussion Papers in Economic and Social History – Oxford University. Brown, S.L. & Brown, R.M. (2006). Selective investment theory: Recasting the functional significance of close relationships. Psychological Inquiry, 17, 1–29. – a theoretical proposal that "human social bonds evolved as overarching, emotion regulating mechanisms designed to promote reliable, high-cost altruism among individuals who depend on one another for survival and reproduction" (From the abstract) Immerman, R.S. & Mackey, W.C. (2003). Perspectives on Human Attachment (Pair Bonding): Eve's unique legacy of canine analogue Evolutionary Psychology, 1, 138–154. ISSN 1474-7049 Thorne, L. (2006). "Of Human Bonding" – Condo Dwellers Find Cool Ways to Connect With the Neighbors, Express (Washingtonpost.com), Mon., (7 Aug.)
Micellar electrokinetic chromatography (MEKC) is a chromatography technique used in analytical chemistry. It is a modification of capillary electrophoresis (CE), extending its functionality to neutral analytes, where the samples are separated by differential partitioning between micelles (pseudo-stationary phase) and a surrounding aqueous buffer solution (mobile phase). The basic set-up and detection methods used for MEKC are the same as those used in CE. The difference is that the solution contains a surfactant at a concentration that is greater than the critical micelle concentration (CMC). Above this concentration, surfactant monomers are in equilibrium with micelles. In most applications, MEKC is performed in open capillaries under alkaline conditions to generate a strong electroosmotic flow. Sodium dodecyl sulfate (SDS) is the most commonly used surfactant in MEKC applications. The anionic character of the sulfate groups of SDS causes the surfactant and micelles to have electrophoretic mobility that is counter to the direction of the strong electroosmotic flow. As a result, the surfactant monomers and micelles migrate quite slowly, though their net movement is still toward the cathode. During a MEKC separation, analytes distribute themselves between the hydrophobic interior of the micelle and hydrophilic buffer solution as shown in figure 1. Analytes that are insoluble in the interior of micelles should migrate at the electroosmotic flow velocity,
Heavy metals, such as lead (Pb), manganese (Mn), iron (Fe), copper (Cu), mercury (Hg), aluminum (Al), bismuth (Bi), zinc (Zn) and selenium (Se) have been linked to PD. They cross the blood-brain barrier, and can disrupt cellular mechanisms, leading to neuroinflammation, oxidative stress, and mitochondrial dysfunction. While some metals like manganese are needed in small amounts for healthy cellular functioning, others like lead are considered toxic at any level of exposure. Lead is considered "one of the most harmful pollutants for human health". Lead-based paint in the United States was banned in 1978. Tetraethyllead was added to gasoline in the United States until the 1990s. As a result, lead was released into the air as part of vehicle exhaust. Lead pipes continue to introduce lead contaminants into water supplies and household water. Following exposure, lead is absorbed into the body where it accumulates in blood, bones, teeth, and soft tissues such as the brain, liver, and kidney. Lead remains in the body and can cause both acute and chronic lead poisoning. Lead is known to damage the central nervous system in a variety of ways, with children being particularly vulnerable. Population studies suggest that higher levels of lead in bone and blood are associated with a higher risk of PD. Lead may be linked to PD through oxidative stress and mitochondrial dysfunction. Regulatory actions and public health measures have contributed to a substantial decrease in the levels of lead exposure measured in the US population since the 1970s.
Sources: en.wikipedia.org
=== Publications === In 2003, Austin released his autobiography The Stone Cold Truth which was co written alongside Jim Ross. The book goes over his entire life up that point from his childhood in Texas to his to the top of the WWE, while also giving behind the scenes look at Austin what he was going through during his career with him sharing his firsthand experiences.
== Chemistry == DET, also known as N,N-diethyltryptamine, is a synthetic compound in the tryptamine class, structurally related to the endogenous neurotransmitter serotonin and the naturally occurring psychedelic compounds dimethyltryptamine (DMT) and dipropyltryptamine (DPT). It is the ethyl analogue of DMT.
== History == APP was founded in 2007 and incorporated in February 2008 by laboratory professionals, Edward Dooling and Thanasis Papaioanu, along with hospital executive, Martin Rash. Edward Dooling was formerly a senior executive with AmeriPath (now part of Quest Diagnostics) and DIANON Systems, Inc., (now part of LabCorp). Thanasis Papaioanu was formerly an investment banker with SunTrust Equitable (now SunTrust Robinson Humphrey) and FTN Financial (part of First Tennessee National Corporation), where he helped launch New York-based laboratory CBLPath, Inc. (now part of Sonic Healthcare). Martin Rash is founder and Chairman/CEO of RegionalCare Hospital Partners; he was formerly founder and Chairman/CEO of publicly traded Province Healthcare Company that was acquired by Lifepoint Hospitals, Inc. (Nasdaq: LPNT) in 2005. In April 2008, APP secured a $75 million equity commitment from New Enterprise Associates (NEA), a large private equity investment firm based in Menlo Park, California and Baltimore, Maryland. On December 31, 2008, APP completed the acquisition of UniPath, LLC in Denver, Colorado. APP operates the technical operation while UniPath, P.C., the affiliated 25+ pathologist medical practice, stays independent and continues to be owned and managed by the pathologists. On March 12, 2009, the firm completed the acquisition of Eastern Carolina Pathology, Inc. in Wilson, North Carolina.
=== Alternative x-axis notations === There are several alternatives to the standard m/z notation that appear in the literature; however, these are not currently accepted by standards organizations and most journals. m/e appears in older historical literature. A label more consistent with the IUPAC green book and ISO 31 conventions is m/Q or m/q where m is the symbol for mass and Q or q the symbol for charge with the units u/e or Da/e. This notation is not uncommon in the physics of mass spectrometry but is rarely used as the abscissa of a mass spectrum. It was also suggested to introduce a new unit thomson (Th) as a unit of m/z, where 1 Th = 1 u/e. According to this convention, mass spectra x axis could be labeled m/z (Th) and negative ions would have negative values. This notation is rare and not accepted by IUPAC or any other standards organisation.
In 2011, the American Society of Pharmacometrics (ASoP) was founded by a number of local American groups, and over 600 members worldwide joined ASoP within 6 months. In 2012, ASoP evolved to the International Society of Pharmacometrics (ISoP) to reflect the increasing number of international members. ISoP's growth continues and the society currently represents over 1000 members from almost 30 countries around the world.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.